Nektar Therapeutics (NKTR) Capital Expenditures (2010 - 2026)
Nektar Therapeutics (NKTR) recorded quarterly Capital Expenditures of $18000.0 in Q1 2026, little changed quarter-over-quarter from $18000.0 in Q4 2025, and up 800.0% on a YoY basis from $2000.0 in Q1 2025.
Nektar Therapeutics (NKTR) Capital Expenditures (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $18000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 800.0% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at $187000.0 (down 85.76% YoY), while the FY2025 annual figure was $171000.0, down 88.35% from the prior year.
- Capital Expenditures was $18000.0 for Q1 2026 at Nektar Therapeutics, roughly flat from $18000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $4.2 million in Q1 2022 to a low of $2000.0 in Q1 2025.
- Historically, Capital Expenditures has averaged $482235.3 across 5 years, with a median of $181000.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures jumped 1918.18% in 2024, then sank 98.73% in 2025.
- A 5-year view of Capital Expenditures shows it stood at $512000.0 in 2022, then sank by 53.71% to $237000.0 in 2023, then soared by 93.67% to $459000.0 in 2024, then plunged by 96.08% to $18000.0 in 2025, then changed by 0.0% to $18000.0 in 2026.
- The last three Capital Expenditures figures came in at $18000.0 (Q1 2026), $18000.0 (Q4 2025), and $114000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Nektar Therapeutics | 1.51 Bn | 939.55 Mn | 3.16 Mn | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Sep 30, 2025 | 114,000.00 |
| Sep 30, 2025 | 114,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 459,000.00 |
| Dec 31, 2024 | 459,000.00 |
| Sep 30, 2024 | 666,000.00 |
| Sep 30, 2024 | 666,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Mar 31, 2024 | 157,000.00 |
| Mar 31, 2024 | 157,000.00 |
| Dec 31, 2023 | 237,000.00 |
| Dec 31, 2023 | 237,000.00 |